No Data
US Stock MarketDetailed Quotes
BMRA Biomerica
Watchlist
1.140
+0.030+2.70% Close 12/11 16:00 ET
1.150High1.090Low29.76KVolume
1.110Open1.110Pre Close33.34KTurnover0.19%Turnover RatioLossP/E (TTM)19.18MMarket Cap3.80052wk HighLossP/E (Static)16.82MShares0.70452wk Low1.78P/B17.77MFloat Cap23.390Historical High--Dividend TTM15.59MShs Float0.170Historical Low--Div YieldTTM5.41%Amplitude1.120Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Biomerica Company
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.
Revenue Breakdown
Business
Currency:USD
2023/05/31
Stock NameRevenueRatio
Design, development, marketing, and sales of diagnostic kits5.34M100.00%
News
Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16
IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum
Biomerica Expands InFoods IBS Reach With Addition of Several New GI Groups
Biomerica remains on track for inFoods IBS national rollout during calendar 2024, and expects strong product revenue growth during national rolloutVeteran Vice President of Sales and National Accounts hired along
JKS, CHRS and BMRA Are Among Pre Market Gainers